A new study from the Cleveland Clinic suggests that semaglutide, marketed as Ozempic and Wegovy, demonstrates effectiveness in achieving long-term weight loss for individuals with obesity. The research identifies dosage and consistent usage as key factors influencing the medication's success.
The study, involving approximately 3,400 patients, found that individuals on higher doses of semaglutide experienced greater weight loss compared to those on lower doses. Furthermore, patients who consistently used the medication for more than 90 days showed more significant results. These findings underscore the importance of adherence to prescribed regimens for optimal outcomes.
Marlee Bruno, a certified physician’s assistant, noted, “Ozempic works by targeting GLP-1 receptors in the brain, which regulate appetite and blood sugar levels, for an effective means of weight control.” She also emphasized that the drug is not a standalone solution and should be used in conjunction with lifestyle changes, such as increased protein intake, hydration, regular exercise, and a healthy diet.
Metabolic Impact of GLP-1 Medications
Research conducted at St Vincent’s University Hospital (SVUH) Dublin challenges the conventional understanding of how GLP-1-based medications work. The study, published in the Journal of the Obesity Society, indicates a strong correlation between increased metabolic activity and weight loss in patients treated with GLP-1 receptor agonists. Notably, individuals with lower initial metabolic activity experienced the most significant benefits.
Professor Donal O’Shea from SVUH stated, “This study challenges the main narrative about these newer treatments which is that they simply make you eat less, and that any action on energy burn is minimal... this increase in metabolic activity is a significant contributor to how these drugs work.”
The study involved specialized imaging of abdominal fat using PET-CT scans before and after six months of GLP-1 treatment in 30 patients. The findings suggest that GLP-1 therapy increases metabolic activity in visceral adipose tissue.
Supply and Demand
The FDA has announced a shortage of Wegovy, citing increased demand. This shortage highlights the growing popularity of semaglutide for weight management and its potential impact on public health. While Ozempic was initially approved in 2017 for Type 2 diabetes, its weight loss benefits have led to widespread use and, subsequently, supply challenges.
Considerations and Risks
As with any medication, semaglutide carries potential risks. The FDA has issued warnings regarding the possibility of overdosing on these products. Additionally, studies suggest that rapid weight loss may lead to decreased bone density, particularly in older adults. It is crucial for patients to use semaglutide under the guidance of a healthcare professional who can monitor progress and adjust dosage as needed.
